In Re Ditropan XL Antitrust Litigation

529 F. Supp. 2d 1098, 2007 WL 1411617
CourtDistrict Court, N.D. California
DecidedMay 11, 2007
DocketM:06-CV-01761-JSW, MDL No. 1761
StatusPublished
Cited by37 cases

This text of 529 F. Supp. 2d 1098 (In Re Ditropan XL Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Ditropan XL Antitrust Litigation, 529 F. Supp. 2d 1098, 2007 WL 1411617 (N.D. Cal. 2007).

Opinion

ORDER (1) GRANTING DEFENDANTS’ MOTION TO DISMISS DIRECT PURCHASER’S COMPLAINT AND (2) GRANTING IN PART AND DENYING IN PART ALZA’S MOTION TO DISMISS INDIRECT PURCHASERS’ COMPLAINT

JEFFREY S. WHITE, District Judge.

Now before the Court are Defendants’ motions to dismiss the two consolidated class action complaints filed by plaintiff American Sales Company (“ASC” or “Direct Purchaser Plaintiff’) 1 and by City of *1100 Fargo Health Trust Fund, Local 28 Sheet Metal Workers Fund, United Food & Commercial Workers Union & Employers Midwest Health Fund, Plumbers & Pipe-fitters Local 572 Health & Welfare Fund, and Teamsters Local No. 35 Health Plans (collectively, “Indirect Purchaser Plaintiffs”). Defendants Alza Corporation (“Alza”) and Johnson & Johnson (collectively, “Defendants”) move jointly to dismiss the Direct Purchaser Plaintiffs action. Alza is the only named defendant in the Indirect Purchaser Plaintiffs’ action, and thus, only Alza moves to dismiss their complaint. Having considered the parties’ arguments, relevant legal authority, and having had the benefit of oral argument, the Court hereby grants the motion to dismiss the Direct Purchaser Plaintiffs complaint and grants in part and denies in part the motion to dismiss the Indirect Purchaser Plaintiffs’ complaint.

BACKGROUND

This is an antitrust action. In essence, the Direct and Indirect Purchaser Plaintiffs allege that Defendants filed a baseless complaint to preclude a competitor from producing a generic version of the drug Ditropan XL, as well as other anti-competitive conduct. They further allege that through such anti-competitive conduct, Alza was able to maintain a monopoly and charge supra-competitive prices for Ditro-pan XL. According to the Direct and Indirect Purchaser Plaintiffs, Defendants’ conduct in delaying or preventing the sale of a generic version of the drug caused them to pay more than they otherwise -would have paid for the drug.

Direct Purchaser Plaintiff brings the following two claims: (1) a claim premised on Section 2 of the Sherman Act and (2) a claim for restitution, disgorgement and constructive trust. Indirect Purchaser Plaintiffs assert the following three claims: (1) a claim under the California Cartwright Act; (2) a claim for violation of California Business and Professions Code section 17200; and (3) a claim for violation of the antitrust statutes of twenty-eight different states — Alabama, Alaska, Arizona, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, Vermont, West Virginia, and Wisconsin.

The Court will address additional specific facts as required in the analysis.

ANALYSIS

A. Direct Purchaser Plaintiffs Complaint.

1. Antitrust Claim.

Admittedly, Direct Purchaser Plaintiff did not purchase Ditropan XL from Alza or Johnson & Johnson. Rather, Direct Purchaser Plaintiffs claims are premised on Cardinal Health, Incorporated’s (“Cardinal”) purchases of Ditropan XL from Ortho-McNeil Pharmaceutical, Incorporated (“Ortho-McNeil”), a wholly owned subsidiary of Johnson & Johnson. Direct Purchaser Plaintiff asserts that Cardinal purportedly assigned its antitrust claims to it. (Declaration of Michael A. Sitzman (“Sitzman Deck”), Ex. 1.) It is undisputed that Direct Purchaser Plaintiff did not directly purchase Ditropan XL from Defendants and that its ability, if any, to maintain a direct purchaser action against Defendants, arises out of its purported assignment from Cardinal. However, Direct Purchaser Plaintiffs complaint fails to allege the existence of the assignment from Cardinal. Without such allegations, any antitrust claims by Direct Purchaser Plaintiff are insufficient. Accordingly, the Court dismisses the Direct *1101 Purchaser Plaintiffs antitrust claim with leave to amend. 2

2. Unjust Enrichment.

At the hearing on Defendants’ motion to dismiss, Direct Purchaser Plaintiff clarified that its unjust enrichment claim is based on state law, but it has not plead under which state or states laws it is based. In fact, Direct Purchaser Plaintiff admitted it is not yet aware of which state or states’ laws it is moving under. Its ability to plead a claim for unjust enrichment may vary from state to state, and unless and until Direct Purchaser Plaintiff clarifies under what state law it is moving, neither Defendants nor the Court can address whether the claim or claims have been adequately plead. Accordingly, the Court dismisses the unjust enrichment claim without prejudice.

B. Indirect Purchaser Plaintiffs’ Complaint.

Indirect Purchaser Plaintiffs concede they are not bringing an antitrust claim under New Jersey law. (Indirect Purchasers’ Opp. at 13.) Accordingly, the Court grants Alza’s motion as to the New Jersey antitrust claim.

1. Unfair Competition Law Claim.

Alza moves to dismiss Indirect Purchaser Plaintiffs’ unfair competition law claim under California Business and Professions Code § 17200 (“UCL”) on the following grounds: (1) the remedy Indirect Purchaser Plaintiffs seek is precluded under the UCL and (2) Indirect Purchaser Plaintiffs failed to allege reliance. 3

*1102 i. The Remedy is not Precluded.

Damages cannot be recovered pursuant to a UCL claim. Korea Supply Co. v. Lockheed Martin Corp., 29 Cal.4th 1134, 1144, 131 Cal.Rptr.2d 29, 63 P.3d 937 (2003). A plaintiff bringing such a claim is limited to injunctive relief and restitution. Id. Indirect Purchaser Plaintiffs do not dispute that they cannot obtain damages for their UCL claim. Instead, they argue that the relief they are seeking is restitu-tionary. Alza, on the other hand, contends that Indirect Purchaser Plaintiffs do not and cannot state a UCL claim because any money lost by them was not taken directly by Alza, and thus, does not qualify as restitution.

In support of its argument, Alza relies primarily on language from the California Supreme Court opinion in Korea Supply. In Korea Supply, the court addressed when disgorgement of a defendant’s profits qualifies as restitution and, thus, is recoverable under UCL claims. Korea Supply, 29 Cal.4th at 1140, 131 Cal.Rptr.2d 29, 63 P.3d 937.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hamm v. Mercedes-Benz USA, LLC
N.D. California, 2022
Carpenter v. Petsmart, Inc.
S.D. California, 2020
Blue Cross of Cal. Inc. v. Insys Therapeutics Inc.
390 F. Supp. 3d 996 (D. Arizona, 2019)
In re Effexor Antitrust Litig.
337 F. Supp. 3d 435 (D. New Jersey, 2018)
In re Lipitor Antitrust Litig.
336 F. Supp. 3d 395 (D. New Jersey, 2018)
In re Epipen
336 F. Supp. 3d 1256 (D. Kansas, 2018)
Becerra v. General Motors LLC
241 F. Supp. 3d 1094 (S.D. California, 2017)
In re Capacitors Antitrust Litigation
154 F. Supp. 3d 918 (N.D. California, 2015)
Senne v. Kansas City Royals Baseball Corp.
114 F. Supp. 3d 906 (N.D. California, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
529 F. Supp. 2d 1098, 2007 WL 1411617, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-ditropan-xl-antitrust-litigation-cand-2007.